News
ABVX
115.98
-2.93%
-3.50
Weekly Report: what happened at ABVX last week (0330-0403)?
Weekly Report · 1d ago
Abivax says JPMorgan Chase beneficial stake rises to 6.2% of capital
Reuters · 4d ago
UBS Group cuts Abivax stake below 5% to 4.11%
Reuters · 4d ago
UBS crosses 5% stake, voting rights thresholds in Abivax, holds 5.28% stake
Reuters · 5d ago
Abivax appoints Michael Nesrallah as chief commercial officer
TipRanks · 5d ago
Abivax files universal registration document, annual report with French AMF
Reuters · 5d ago
Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)
Seeking Alpha · 6d ago
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout
Benzinga · 03/31 14:48
Weekly Report: what happened at ABVX last week (0323-0327)?
Weekly Report · 03/30 09:31
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst
TipRanks · 03/28 14:37
Abivax Feb. 28, 2026 issued shares rise to 79.2 million; total voting rights grow to 81.5 million
Reuters · 03/27 19:16
Abivax notified beneficial ownership; UBS Group drops to 3.23 million shares, 4.11% of capital and 3.99% of voting rights
Reuters · 03/27 11:07
Abivax notified UBS Group beneficial ownership rises to 4.1 million shares; stake climbs to 5.28% of capital
Reuters · 03/26 16:06
Abivax SA (0RA9) Receives a Rating Update from a Top Analyst
TipRanks · 03/26 07:39
Abivax: Going It Alone At A Premium (Rating Downgrade)
Seeking Alpha · 03/25 13:40
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim
TipRanks · 03/25 10:59
Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
Benzinga · 03/24 17:53
Abivax CEO suggests no urgency for deal-making ahead of key trial readout
Seeking Alpha · 03/24 17:04
Barclays Maintains Overweight on Abivax, Raises Price Target to $148
Benzinga · 03/24 14:00
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ADR (ABVX)
TipRanks · 03/24 13:10
More
Webull provides a variety of real-time ABVX stock news. You can receive the latest news about Abivax S.A. through multiple platforms. This information may help you make smarter investment decisions.
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.